- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes (T2DM)
- Interventions
- SGLT-2 inhibitor, GLP1-RA
- Drug
- Lead sponsor
- MaryAnn Banerji
- Other
- Eligibility
- 24 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Upper Endoscopy, GLP1-R-related Disease
- Interventions
- Modified Fasting Guidelines
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity
- Interventions
- Liraglutide, Oral Semaglutide, Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Pregnancy, Obesity, Overweight
- Interventions
- No Intervention
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 15 Years to 50 Years · Female only
- Enrollment
- 728 participants
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Nutrition Intake, Nutrition Status, Gastrointestinal Microbiome, GLP-1
- Interventions
- AG1 - Nutritional Supplement, Placebo
- Dietary Supplement
- Lead sponsor
- Athletic Greens International
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Semaglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 14
- States / cities
- Buena Park, California • Fresno, California • San Jose, California + 11 more
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
- Interventions
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Drug · Diagnostic Test
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Interventions
- ellacor
- Device
- Lead sponsor
- Cytrellis Biosystems, Inc.
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dublin, California
- Conditions
- Muscle Composition, Obesity, Quality of Life (QOL)
- Interventions
- Resistance Exercise, GLP-1 RAs
- Behavioral · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lymphedema
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Advanced Reconstructive Surgery Alliance
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Red Bank, New Jersey • Westwood, New Jersey
- Conditions
- Lactation, Weight Loss
- Interventions
- Injected GLP-1 Receptor Agonists and Dual Agonists
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado